121 123

Cited 25 times in

Site-specific metabolic phenotypes in metastatic breast cancer.

Authors
 Hye Min Kim  ;  Woo Hee Jung  ;  Ja Seung Koo 
Citation
 Journal of Translational Medicine, Vol.12 : 1-17, 2014 
Journal Title
 Journal of Translational Medicine 
ISSN
 1479-5876 
Issue Date
2014
MeSH
Breast Neoplasms/metabolism* ; Breast Neoplasms/pathology ; Female ; Humans ; Middle Aged ; Neoplasm Metastasis* ; Phenotype
Keywords
Breast ; Metabolism ; Metastasis
Abstract
BACKGROUND: The purpose of this study was to examine the expression of metabolism-related proteins according to metastatic site in metastatic breast cancer and to assess the implication of site-specific differential expression. METHODS: A tissue microarray containing 162 cases of metastatic breast cancer (52 lung metastasis, 47 bone metastasis, 39 brain metastasis, and 24 liver metastasis) was constructed. It was subject to immunohistochemical staining of the following proteins: Glycolysis-related: Glut-1, hexolinase II, carbonic anhydrase (CA) IX, and monocarboxylate transporter (MCT) 4; glutaminolysis-related: glutaminase (GLS) 1, glutamate dehydrogenase (GDH), and amino acid transporter (ASCT) 2; mitochondrial metabolism-related: ATP synthase, succinate dehydrogenase (SDH)A, and SDHB; and serine/glycine metabolism related: phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase (PSAT), phosphoserine phosphatase (PSPH), glycine decarboxylase (GLDC), and serine hydroxymethyltransferase (SHMT). RESULTS: The expression levels of glycolysis-related-proteins (Glut-1, hexokinase II, CAIX, and MCT4) differed according to metastatic site, with higher expression seen in the brain and lower expression in the bone and liver (p < 0.001, 0.001, 0.009, and <0.001, respectively). Differences in metabolic phenotype were analyzed according to metastasis site. Glycolysis type was most frequently encountered in the brain and lung (p < 0.001). In univariate analysis, the factors associated with shorter overall survival were CAIX positivity (p = 0.044), PSPH positivity (p = 0.045), and SHMT1 positivity (p = 0.002), as well as serine/glycine type (p = 0.041). CONCLUSIONS: Differences in metabolic features according to metastatic site were seen in metastatic breast cancer, with the glycolysis phenotype found predominantly in the brain and lung and the non-glycolysis phenotype in the bone and liver.
Files in This Item:
T201405257.pdf Download
DOI
10.1186/s12967-014-0354-3
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Koo, Ja Seung(구자승) ORCID logo https://orcid.org/0000-0003-4546-4709
Kim, Hye Min(김혜민) ORCID logo https://orcid.org/0000-0002-2899-9480
Jung, Woo Hee(정우희)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138665
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse